{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:30:17Z","timestamp":1787020217992,"version":"build-2736575974"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,6,27]],"date-time":"2018-06-27T00:00:00Z","timestamp":1530057600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2018,6,27]],"date-time":"2018-06-27T00:00:00Z","timestamp":1530057600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA202762"],"award-info":[{"award-number":["R01CA202762"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12885-018-4605-1","type":"journal-article","created":{"date-parts":[[2018,6,26]],"date-time":"2018-06-26T20:26:10Z","timestamp":1530044770000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":79,"title":["Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience"],"prefix":"10.1186","volume":"18","author":[{"given":"Danielle C.","family":"Glassman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randze L.","family":"Palmaira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina M.","family":"Covington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avni M.","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey Y.","family":"Ku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James J.","family":"Harding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna M.","family":"Varghese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen M.","family":"O\u2019Reilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4774-2672","authenticated-orcid":false,"given":"Kenneth H.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,6,27]]},"reference":[{"issue":"1","key":"4605_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21387","volume":"67","author":"RL Siegel","year":"2017","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7\u201330. \n                    https:\/\/doi.org\/10.3322\/caac.21387\n                    \n                  .","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"4605_CR2","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","volume":"74","author":"L Rahib","year":"2014","unstructured":"Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74(11):2913\u201321. \n                    https:\/\/doi.org\/10.1158\/0008-5472.CAN-14-0155\n                    \n                  .","journal-title":"Cancer Res"},{"issue":"19","key":"4605_CR3","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817\u201325. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1011923\n                    \n                  .","journal-title":"N Engl J Med"},{"issue":"18","key":"4605_CR4","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691\u2013703. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1304369\n                    \n                  .","journal-title":"N Engl J Med"},{"issue":"6","key":"4605_CR5","doi-asserted-by":"publisher","first-page":"3271","DOI":"10.1158\/0008-5472.CAN-05-4007","volume":"66","author":"DC Drummond","year":"2006","unstructured":"Drummond DC, Noble CO, Guo Z, Hong K, Park JW, Kirpotin DB. Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy. Cancer Res. 2006;66(6):3271\u20137. \n                    https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-4007\n                    \n                  .","journal-title":"Cancer Res"},{"issue":"9","key":"4605_CR6","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1038\/bjc.2016.306","volume":"115","author":"EG Chiorean","year":"2016","unstructured":"Chiorean EG, Von Hoff DD, Tabernero J, El-Maraghi R, Wee Ma W, Reni M, et al. Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer. Br J Cancer. 2016;115(9):e13. \n                    https:\/\/doi.org\/10.1038\/bjc.2016.306.","journal-title":"Br J Cancer"},{"issue":"8","key":"4605_CR7","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1634\/theoncologist.2016-0447","volume":"22","author":"TA Abrams","year":"2017","unstructured":"Abrams TA, Meyer G, Meyerhardt JA, Wolpin BM, Schrag D, Fuchs CS. Patterns of chemotherapy use in a U.S.-based cohort of patients with metastatic pancreatic Cancer. Oncologist. 2017;22(8):925\u201333. \n                    https:\/\/doi.org\/10.1634\/theoncologist.2016-0447\n                    \n                  .","journal-title":"Oncologist"},{"issue":"10018","key":"4605_CR8","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S0140-6736(15)00986-1","volume":"387","author":"A Wang-Gillam","year":"2016","unstructured":"Wang-Gillam A, Li CP, Bodoky G, Dean A, Shan YS, Jameson G, et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet. 2016;387(10018):545\u201357. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(15)00986-1\n                    \n                  .","journal-title":"Lancet"},{"issue":"5897","key":"4605_CR9","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1126\/science.1164368","volume":"321","author":"S Jones","year":"2008","unstructured":"Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008;321(5897):1801\u20136.","journal-title":"Science"},{"issue":"7319","key":"4605_CR10","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1038\/nature09515","volume":"467","author":"S Yachida","year":"2010","unstructured":"Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature. 2010;467(7319):1114\u20137.","journal-title":"Nature"},{"issue":"7424","key":"4605_CR11","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nature11547","volume":"491","author":"AV Biankin","year":"2012","unstructured":"Biankin AV, Waddell N, Kassahn KS, Gingras MC, Muthuswamy LB, Johns AL, et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature. 2012;491(7424):399\u2013405. \n                    https:\/\/doi.org\/10.1038\/nature11547\n                    \n                  .","journal-title":"Nature"},{"issue":"7540","key":"4605_CR12","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nature14169","volume":"518","author":"N Waddell","year":"2015","unstructured":"Waddell N, Pajic M, Patch AM, Chang DK, Kassahn KS, Bailey P, et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. 2015;518(7540):495\u2013501. \n                    https:\/\/doi.org\/10.1038\/nature14169\n                    \n                  .","journal-title":"Nature"},{"issue":"7592","key":"4605_CR13","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature16965","volume":"531","author":"P Bailey","year":"2016","unstructured":"Bailey P, Chang DK, Nones K, Johns AL, Patch AM, Gingras MC, et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature. 2016;531(7592):47\u201352. \n                    https:\/\/doi.org\/10.1038\/nature16965\n                    \n                  .","journal-title":"Nature"},{"issue":"9","key":"4605_CR14","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1001\/jama.2017.11137","volume":"318","author":"D Mandelker","year":"2017","unstructured":"Mandelker D, Zhang L, Kemel Y, Stadler ZK, Joseph V, Zehir A, et al. Mutation detection in patients with advanced Cancer by universal sequencing of Cancer-related genes in tumor and normal DNA vs guideline-based germline testing. JAMA. 2017;318(9):825\u201335. \n                    https:\/\/doi.org\/10.1001\/jama.2017.11137\n                    \n                  .","journal-title":"JAMA"},{"issue":"20","key":"4605_CR15","doi-asserted-by":"publisher","first-page":"6094","DOI":"10.1158\/1078-0432.CCR-17-0899","volume":"23","author":"MA Lowery","year":"2017","unstructured":"Lowery MA, Jordan EJ, Basturk O, Ptashkin RN, Zehir A, Berger MF, et al. Real-time genomic profiling of pancreatic ductal adenocarcinoma: potential Actionability and correlation with clinical phenotype. Clin Cancer Res. 2017;23(20):6094\u2013100. \n                    https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-0899\n                    \n                  .","journal-title":"Clin Cancer Res"},{"issue":"7","key":"4605_CR16","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1038\/bjc.2015.328","volume":"113","author":"A Portal","year":"2015","unstructured":"Portal A, Pernot S, Tougeron D, Arbaud C, Bidault AT, de la Fouchardiere C, et al. Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort. Br J Cancer. 2015;113(7):989\u201395. \n                    https:\/\/doi.org\/10.1038\/bjc.2015.328\n                    \n                  .","journal-title":"Br J Cancer"},{"issue":"6","key":"4605_CR17","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1007\/s00280-012-1875-1","volume":"69","author":"A Zaniboni","year":"2012","unstructured":"Zaniboni A, Aitini E, Barni S, Ferrari D, Cascinu S, Catalano V, et al. FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study. Cancer Chemother Pharmacol. 2012;69(6):1641\u20135. \n                    https:\/\/doi.org\/10.1007\/s00280-012-1875-1\n                    \n                  .","journal-title":"Cancer Chemother Pharmacol"},{"issue":"23","key":"4605_CR18","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1200\/JCO.2013.53.6995","volume":"32","author":"H Oettle","year":"2014","unstructured":"Oettle H, Riess H, Stieler JM, Heil G, Schwaner I, Seraphin J, et al. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. J Clin Oncol. 2014;32(23):2423\u20139. \n                    https:\/\/doi.org\/10.1200\/JCO.2013.53.6995\n                    \n                  .","journal-title":"J Clin Oncol"},{"issue":"32","key":"4605_CR19","doi-asserted-by":"publisher","first-page":"3914","DOI":"10.1200\/JCO.2016.68.5776","volume":"34","author":"S Gill","year":"2016","unstructured":"Gill S, Ko YJ, Cripps C, Beaudoin A, Dhesy-Thind S, Zulfiqar M, et al. PANCREOX: a randomized phase III study of fluorouracil\/Leucovorin with or without Oxaliplatin for second-line advanced pancreatic Cancer in patients who have received gemcitabine-based chemotherapy. J Clin Oncol. 2016;34(32):3914\u201320. \n                    https:\/\/doi.org\/10.1200\/JCO.2016.68.5776\n                    \n                  .","journal-title":"J Clin Oncol"},{"issue":"10","key":"4605_CR20","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1038\/sj.bjc.6605374","volume":"101","author":"C Yoo","year":"2009","unstructured":"Yoo C, Hwang JY, Kim JE, Kim TW, Lee JS, Park DH, et al. A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer. Br J Cancer. 2009;101(10):1658\u201363. \n                    https:\/\/doi.org\/10.1038\/sj.bjc.6605374\n                    \n                  .","journal-title":"Br J Cancer"},{"issue":"23","key":"4605_CR21","doi-asserted-by":"publisher","first-page":"4680","DOI":"10.1002\/cncr.30927","volume":"123","author":"MB Sonbol","year":"2017","unstructured":"Sonbol MB, Firwana B, Wang Z, Almader-Douglas D, Borad MJ, Makhoul I, et al. Second-line treatment in patients with pancreatic ductal adenocarcinoma: a meta-analysis. Cancer. 2017;123(23):4680\u20136. \n                    https:\/\/doi.org\/10.1002\/cncr.30927\n                    \n                  .","journal-title":"Cancer"},{"issue":"3","key":"4605_CR22","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s00280-014-2671-x","volume":"75","author":"TC Chang","year":"2015","unstructured":"Chang TC, Shiah HS, Yang CH, Yeh KH, Cheng AL, Shen BN, et al. Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients. Cancer Chemother Pharmacol. 2015;75(3):579\u201386. \n                    https:\/\/doi.org\/10.1007\/s00280-014-2671-x\n                    \n                  .","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"4605_CR23","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1038\/bjc.2013.408","volume":"109","author":"AH Ko","year":"2013","unstructured":"Ko AH, Tempero MA, Shan YS, Su WC, Lin YL, Dito E, et al. A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer. Br J Cancer. 2013;109(4):920\u20135. \n                    https:\/\/doi.org\/10.1038\/bjc.2013.408\n                    \n                  .","journal-title":"Br J Cancer"},{"issue":"Suppl 2","key":"4605_CR24","doi-asserted-by":"publisher","first-page":"ii110-ii","DOI":"10.1093\/annonc\/mdw200.23","volume":"27","author":"LT Chen","year":"2016","unstructured":"Chen LT, Siveke J, Wang-Gillam A, Hubner R, Pant S, Dragovich T, et al. PD-023Safety across subgroups in NAPOLI-1: a phase 3 study of nal-IRI (MM-398) \u00b1 5-fluorouracil and leucovorin (5-FU\/LV) versus 5-FU\/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy. Ann Oncol. 2016;27(Suppl 2):ii110-ii. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdw200.23\n                    \n                  .","journal-title":"Ann Oncol"},{"issue":"2","key":"4605_CR25","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1177\/1758834016676011","volume":"9","author":"DH Ahn","year":"2017","unstructured":"Ahn DH, Krishna K, Blazer M, Reardon J, Wei L, Wu C, et al. A modified regimen of biweekly gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer is both tolerable and effective: a retrospective analysis. Ther Adv Med Oncol. 2017;9(2):75\u201382. \n                    https:\/\/doi.org\/10.1177\/1758834016676011\n                    \n                  .","journal-title":"Ther Adv Med Oncol"},{"key":"4605_CR26","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.canlet.2017.07.012","volume":"406","author":"X Li","year":"2017","unstructured":"Li X, Ma T, Zhang Q, Chen YG, Guo CX, Shen YN, et al. Modified-FOLFIRINOX in metastatic pancreatic cancer: a prospective study in Chinese population. Cancer Lett. 2017;406:22\u20136. \n                    https:\/\/doi.org\/10.1016\/j.canlet.2017.07.012\n                    \n                  .","journal-title":"Cancer Lett"},{"issue":"4_suppl","key":"4605_CR27","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1200\/JCO.2018.36.4_suppl.469","volume":"36","author":"A Ohba","year":"2018","unstructured":"Ohba A, Ueno H, Sakamoto Y, Kondo S, Morizane C, Okusaka T. Retrospective comparison of modified FOLFIRINOX with full-dose FOLFIRINOX for advanced pancreatic cancer: A Japanese cancer center experience. J Clin Oncol. 2018;36(4_suppl):469. \n                    https:\/\/doi.org\/10.1200\/JCO.2018.36.4_suppl.469\n                    \n                  .","journal-title":"J Clin Oncol"},{"key":"4605_CR28","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.ejca.2017.02.010","volume":"76","author":"JC Lee","year":"2017","unstructured":"Lee JC, Kim JW, Ahn S, Kim HW, Lee J, Kim YH, et al. Optimal dose reduction of FOLFIRINOX for preserving tumour response in advanced pancreatic cancer: using cumulative relative dose intensity. Eur J Cancer. 2017;76:125\u201333. \n                    https:\/\/doi.org\/10.1016\/j.ejca.2017.02.010\n                    \n                  .","journal-title":"Eur J Cancer"},{"issue":"3","key":"4605_CR29","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1097\/MPA.0000000000000760","volume":"46","author":"H Hayashi","year":"2017","unstructured":"Hayashi H, Kohno T, Ueno H, Hiraoka N, Kondo S, Saito M, et al. Utility of assessing the number of mutated KRAS, CDKN2A, TP53, and SMAD4 genes using a targeted deep sequencing assay as a prognostic biomarker for pancreatic Cancer. Pancreas. 2017;46(3):335\u201340. \n                    https:\/\/doi.org\/10.1097\/MPA.0000000000000760\n                    \n                  .","journal-title":"Pancreas"},{"issue":"2","key":"4605_CR30","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1097\/MPA.0b013e3181f95104","volume":"40","author":"LF Grochola","year":"2011","unstructured":"Grochola LF, Taubert H, Greither T, Bhanot U, Udelnow A, Wurl P. Elevated transcript levels from the MDM2 P1 promoter and low p53 transcript levels are associated with poor prognosis in human pancreatic ductal adenocarcinoma. Pancreas. 2011;40(2):265\u201370.","journal-title":"Pancreas"},{"issue":"1","key":"4605_CR31","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s12253-012-9555-3","volume":"19","author":"Y Luo","year":"2013","unstructured":"Luo Y, Tian L, Feng Y, Yi M, Chen X, Huang Q. The predictive role of p16 deletion, p53 deletion, and polysomy 9 and 17 in pancreatic ductal adenocarcinoma. Pathol Oncol Res. 2013;19(1):35\u201340. \n                    https:\/\/doi.org\/10.1007\/s12253-012-9555-3\n                    \n                  .","journal-title":"Pathol Oncol Res"},{"issue":"14","key":"4605_CR32","doi-asserted-by":"publisher","first-page":"4674","DOI":"10.1158\/1078-0432.CCR-09-0227","volume":"15","author":"A Blackford","year":"2009","unstructured":"Blackford A, Serrano OK, Wolfgang CL, Parmigiani G, Jones S, Zhang X, et al. SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer. Clin Cancer Res. 2009;15(14):4674\u20139. \n                    https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-0227\n                    \n                  .","journal-title":"Clin Cancer Res"},{"issue":"9","key":"4605_CR33","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1038\/sj.onc.1207299","volume":"23","author":"M Abal","year":"2004","unstructured":"Abal M, Bras-Goncalves R, Judde JG, Fsihi H, De Cremoux P, Louvard D, et al. Enhanced sensitivity to irinotecan by Cdk1 inhibition in the p53-deficient HT29 human colon cancer cell line. Oncogene. 2004;23(9):1737\u201344. \n                    https:\/\/doi.org\/10.1038\/sj.onc.1207299\n                    \n                  .","journal-title":"Oncogene"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-4605-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-018-4605-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-4605-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,14]],"date-time":"2020-05-14T09:26:21Z","timestamp":1589448381000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-018-4605-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,27]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["4605"],"URL":"https:\/\/doi.org\/10.1186\/s12885-018-4605-1","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,27]]},"assertion":[{"value":"1 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This retrospective analysis was granted a research waiver by the MSKCC Institutional Review Board. The need for informed consent has been waived by the MSKCC IRB per 45 CFR 46.116 and 45 CFR 164.512.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"KHY (consultant or advisory role, Ipsen), EOR (consultant or advisory role, Ipsen).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"693"}}